Copyright
©The Author(s) 2023.
World J Psychiatry. Nov 19, 2023; 13(11): 937-948
Published online Nov 19, 2023. doi: 10.5498/wjp.v13.i11.937
Published online Nov 19, 2023. doi: 10.5498/wjp.v13.i11.937
Table 3 Summary of adverse events and adverse drug reactions (n = 894)
| Category | n | % |
| Any AE | 101 | 11.3% |
| Any ADR | 78 | 8.7% |
| AE leading to discontinuation | 14 | 1.6% |
| ADR leading to discontinuation | 12 | 1.3% |
| EPS AE | 29 | 3.1% |
| EPS ADR | 25 | 2.7% |
| EPS AE leading to discontinuation | 3 | 0.3% |
| EPS ADR leading to discontinuation | 3 | 0.3% |
| Serious AE | 1 | 0.1% |
| Serious ADR | 1 | 0.1% |
- Citation: Wei YM, Wang XJ, Yang XD, Wang CS, Wang LL, Xu XY, Zhao GJ, Li B, Zhu DM, Wu Q, Shen YF. Safety and effectiveness of lurasidone in the treatment of Chinese schizophrenia patients: An interim analysis of post-marketing surveillance. World J Psychiatry 2023; 13(11): 937-948
- URL: https://www.wjgnet.com/2220-3206/full/v13/i11/937.htm
- DOI: https://dx.doi.org/10.5498/wjp.v13.i11.937